revenue had a weak quarter. The effects of the sales dip in the CDMO category
were mitigated by a strong quarter for royalty sales which resulted in a
healthy bottom line. Magle Chemoswed continues to shift towards high-margin
business areas such as DSM sales and royalties combined with a solid cost
control. During the quarter, the company has initiated an investment program
to increase production capacity for proprietary products.
Aktuellt
SENASTE
